Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 29.57% is 190% above its 5-year average of 10.19%, near the high end of its 5-year range (6.59%–29.57%).
As of the fiscal period ended Tuesday, June 30, 2026. 41.48% above its 12-month average of 20.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.57%.
DEBT TO ASSETS RATIO
29.57%
DEBT TO ASSETS RATIO AVG TTM
20.90%
DEBT TO ASSETS RATIO AVG 3Y
11.74%
DEBT TO ASSETS RATIO AVG 5Y
10.19%
DEBT TO ASSETS RATIO AVG 10Y
6.37%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+41.48%
CURRENT VS 3Y AVG
+151.77%
CURRENT VS 5Y AVG
+190.20%
CURRENT VS 10Y AVG
+364.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.29%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+10274.32%
vs the sector median at left
CRISPR Therapeutics AG
Market Cap
$5.35B
Debt to Assets Ratio
29.57%
TTM Avg
20.90%
3Y Avg
11.74%
5Y Avg
10.19%
Market Cap
$5.10B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.61B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.47B
Debt to Assets Ratio
0.43%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.76B
Debt to Assets Ratio
0.59%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.52B
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.35B | 29.57% | 20.90% | 11.74% | 10.19% |
| Doximity, Inc. (DOCS)vs › | $5.22B | 0.01% | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 0.29% | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | 0.39% | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | 0.43% | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.63B | 0.21% | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 0.59% | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | 0.04% | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | 0.18% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | 0.05% | N/A | N/A | N/A |
Debt/Assets
29.6%
Debt/Equity
0.45
Current Ratio
17.85
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 29.57% |
| 2026-03-31 | 28.90% |
| 2025-12-31 | 17.43% |
| 2025-09-30 | 17.98% |
| 2025-06-30 | 10.61% |
| 2025-03-31 | 10.13% |
| 2024-12-31 | 9.98% |
| 2024-09-30 | 10.09% |
| 2024-06-30 | 9.89% |
| 2024-03-31 | 9.63% |
| 2023-12-31 | 10.70% |
| 2023-09-30 | 11.58% |
| 2023-06-30 | 11.16% |
| 2023-03-31 | 10.71% |
| 2022-12-31 | 10.88% |
| 2022-09-30 | 10.29% |
| 2022-06-30 | 9.84% |
| 2022-03-31 | 9.17% |
| 2021-12-31 | 8.18% |
| 2021-09-30 | 7.28% |
| 2021-06-30 | 6.59% |
| 2021-03-31 | 3.14% |
| 2020-12-31 | 3.36% |
| 2020-09-30 | 3.31% |
| 2020-06-30 | 4.80% |
| 2020-03-31 | 5.10% |
| 2019-12-31 | 4.93% |
| 2019-09-30 | 5.78% |
| 2019-06-30 | 8.51% |
| 2019-03-31 | 7.36% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 24.05% |
